DIRS.INFO The most relevant business & tech news

☆ Eli Lilly's weight loss drug Zepbound cuts heart failure risks in late-stage study
▼ + stars: | 2024-08-01 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York, US, on Thursday, March 28, 2024. Eli Lilly 's weight loss drug Zepbound showed benefits in patients with a common type of heart failure and obesity, according to late-stage trial data the company released Thursday. Eli Lilly said it plans to submit the results from the phase three trial to regulators in the U.S. and other agencies starting later this year. Zepbound also significantly improved heart failure symptoms and physical limitations, Eli Lilly said in a release. Eli Lilly will present the data at an upcoming medical meeting and submit it to a peer-reviewed journal.

Persons: Eli Lilly, Zepbound Organizations: Centers for Disease Control, Novo Nordisk, Drug Administration Locations: Brooklyn, New York, U.S

☆ Chrissy Teigen and John Legend’s son Miles was diagnosed with type 1 diabetes
▼ + stars: | 2024-08-01 | by ( Alli Rosenbloom | ) edition.cnn.com time to read: +2 min

CNN —Chrissy Teigen has shared that her six-year-old son Miles has been diagnosed with type 1 diabetes. Teigen, who has four children with EGOT-winner John Legend, wrote about their son’s diagnosis on Instagram after some commenters noticed that Miles appeared to be wearing a diabetes monitor in a photo with Teigen and his sister, Luna, 8, at the Paris Olympics. “A lot of you noticed something a little special about a photo I posted a few days ago,” she wrote. “You noticed his type-1 diabetes monitor and extended so much love and encouragement in every way possible.”Teigen said Miles was diagnosed just a couple of weeks ago, when he was “sick, in the hospital” with an unrelated infection. Type 1 diabetes is “a disease of high blood sugars due to a deficiency of insulin production,” according to Dr. Otis Brawley, Chief Medical Officer of the American Cancer Society.

Persons: Chrissy Teigen, Miles, Teigen, John Legend, Luna, ”, “, ” Teigen, I’ve, , Otis Brawley Organizations: CNN, Paris, American Cancer Society

☆ A nutritionist who cut down on ultra-processed foods quit protein shakes and bars. Here are 3 things he would eat after a workout instead.
▼ + stars: | 2024-08-01 | by ( Kim Schewitz | ) www.businessinsider.com time to read: +4 min

Read previewA nutritionist who works out six times a week changed his post-workout snacks after he decided to cut down on ultra-processed foods. They usually have a long shelf life, come in highly marketed packaging, and are made to be ultra-palatable, Hobson previously told BI. "I'm sure in my life I will eat another protein bar if that's all that's available. Have a minimally processed protein shakeOn days when he can't make it home after the gym, Hobson will have a simple protein shake made with whey protein. When he is able to make it home but needs to rush out, he makes a protein shake using almost exclusively whole-food ingredients.

Persons: —, Rob Hobson, Hobson, hasn't, Alix Turoff Organizations: Service, Business, Northeastern University's Network Science Institute

☆ Replacing red meat cuts dementia risk by 20%, study says
▼ + stars: | 2024-07-31 | by ( Sandee Lamotte | ) edition.cnn.com time to read: +7 min

The risk for dementia dropped by 20%, however, for people who replaced that small daily serving of processed red meat with a daily serving of nuts and legumes. Processed red meats such as bacon, sausage, hot dogs and deli meats often contain higher levels of sodium, nitrates and saturated fat. Each additional serving of processed red meat raised riskAn abstract of the study, which is under review for publication, was presented Wednesday at the 2024 Alzheimer’s Association International Conference in Philadelphia. Red meat intake is limited. Red meat, especially processed red meat as seen here, is linked to an unhealthy heart and brain.

Persons: ”, Walter Willett, ” Willett, David Katz, Katz, Maria Carrillo, Tanja Ivanova, Yuhan Li, Li, Christopher Gardner, ” Gardner, chia, sprinkle chia Organizations: CNN, Harvard, of Public Health, True Health Initiative, International Conference, Nurses, Alzheimer’s Association, Getty, Division, Network Medicine, Brigham, Women’s Hospital, Stanford Prevention Research, Nutrition Studies Research Locations: Chan, Boston, Philadelphia, bologna, lima, California

☆ Commonly used drug may extend women’s fertility, claim researchers – here’s what you need to know about rapamycin
▼ + stars: | 2024-07-31 | by ( Stephane Berneau | University Of Central Lancashire | ) edition.cnn.com time to read: +7 min

This early-established ovarian reserve can affect a person’s ability to become pregnant throughout their reproductive years. As a woman ages, her ovarian reserve diminishes until she has only a limited number of good-quality follicles remaining. The average age of menopause is 51 years – though this can vary broadly between women depending on their ovarian reserve. The ovarian reserve was monitored by transvaginal ultrasound and several blood tests to detect various ovarian hormones. But if the clinical trial shows rapamycin is beneficial, this could help women with low ovarian reserve and those hoping to prolong their fertility.

Persons: it’s, It’s, rapamycin, We’re, Stéphane Berneau Organizations: CNN, Research, University of Central, Society, Biochemical Society, Alzheimer’s Research, Anatomical Society Locations: University of Central Lancashire

☆ Tackle these 14 factors to lower dementia risk, report suggests
▼ + stars: | 2024-07-31 | by ( Kristen Rogers | ) edition.cnn.com time to read: +8 min

But addressing 14 risk factors over the course of one’s life — starting in childhood — could prevent or delay nearly half of cases, according to a large report by 27 dementia experts. “The progress in preventing and treating dementia is accelerating.”The initial 12 risk factors were linked with 40% of cases, but the new report suggests addressing the 14 risk factors could help eliminate or delay 45% of dementia cases, said Livingston, a professor of psychiatry of older people at University College London. This “critical” update calls attention to two risk factors that preventive neurologist Dr. Richard Issacson says his clinical practice has been evaluating for over a decade. Influencing brain functionThe report doesn’t establish with certainly that these risk factors directly cause dementia, experts said. But other research has provided theories on the link between these vulnerabilities and dementia risk.

Persons: CNN —, ”, Dr, Gill Livingston, Livingston, Richard Issacson, Isaacson, wasn’t, It’s, Klaus Ebmeier, Ebmeier wasn’t, ” Livingston, Glen R, Finney, Alzheimer’s, Susan Kohlhaas, Kohlhaas, …, ” Finney Organizations: CNN, Lancet, University College London, University of Oxford, American Academy of Neurology, Alzheimer’s Research Locations: midlife, Florida, Wilkes Barre , Pennsylvania, €

☆ Amazon projected huge losses from its healthcare business in 2024, but strong sales growth, internal document reveals
▼ + stars: | 2024-07-30 | by ( Eugene Kim | ) www.businessinsider.com time to read: +7 min

Read previewLate last year, Amazon projected its healthcare businesses to lose more than $1 billion for 2024, according to an internal planning document obtained by Business Insider. Although the company doesn't breakout financials on the healthcare business, investors will be looking for signs of success when it reports results on Thursday. That was mostly thanks to Amazon Pharmacy, which was projected to generate $1.81 billion in 2024 sales, a 45% surge. Amazon healthcare is slowing investments in smaller initiatives by delaying hiring for certain projects and reducing contractor spend, it added. It's upgrading the signup process, such as insurance card capture technology, and simplifying the linking between One Medical and Amazon Pharmacy accounts.

Persons: —, Andy Jassy, Brand, Neil Lindsay, It's Organizations: Service, Business, Amazon, Pharmacy, Amazon Health Services, Tech, Amazon Pharmacy, Health Services, Health, Amazon Clinic, Google

☆ North Korea is looking for medicine overseas to treat Kim Jong Un's obesity, spy agency says
▼ + stars: | 2024-07-30 | by ( Mikhaila Friel | ) www.businessinsider.com time to read: +1 min

North Korea is seeking medicine for Kim Jong Un's obesity, a South Korean spy agency said. Kim, 40, is said to weigh 308 pounds and have high blood pressure and diabetes. Sign up to get the inside scoop on today’s biggest stories in markets, tech, and business — delivered daily. download the app Email address Sign up By clicking “Sign Up”, you accept our Terms of Service and Privacy Policy . AdvertisementNorth Korean officials are looking to find new drugs to treat Kim Jong Un's obesity-related health issues, South Korea's spy agency said.

Persons: Kim Jong, Kim, —, Kim —, Lee Seong Kweun Organizations: Service, National Intelligence Service, AP News, Business Locations: Korea, South Korean

☆ Weight-loss drugs could stave off dementia, small study finds
▼ + stars: | 2024-07-30 | by ( Hilary Brueck | ) www.businessinsider.com time to read: +6 min

Today, a group of dementia researchers from the UK released some early results that suggest it's possible these trendy injections might also stall the progression of dementia. A daily injection for brain preservationIuliia Burmistrova/Getty ImagesFor the study, researchers spent a year tracking brain changes across 204 Alzheimer's patients with mild to moderate disease. "It sounds like it is worth pursuing a larger trial, but these results cannot demonstrate that liraglutide can protect against dementia." Experts have seen how dementia patients' brains get worse and worse at efficiently using glucose for energy as their disease progresses, but the calculus is always complicated. Bigger studies using more powerful GLP-1 drugs for dementia are already ongoing.

Persons: Stephen Evans, Jason Kirk, Quynh Nguyen, hadn't, Dr, Paul Edison, it's, Edison, Alzheimer's Organizations: Service, Alzheimer's Association International Conference, London School of Hygiene, Medicine, Science Media, Nikon, Imperial College London, Food and Drug Administration, Novo Nordisk Locations: Philadelphia, Novo

☆ Scientists say weight-loss drugs could protect our brains from dementia. Early results suggest they're onto something.
▼ + stars: | 2024-07-30 | by ( Hilary Brueck | ) www.businessinsider.com time to read: +6 min

☆ Older GLP-1 drug from Novo Nordisk may slow Alzheimer's disease progression by protecting the brain, study says
▼ + stars: | 2024-07-30 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +5 min

George Frey | ReutersAn older, once-daily drug for diabetes and obesity from Novo Nordisk called liraglutide may slow the progression of Alzheimer's disease by protecting patients' brains, according to data from a mid-stage trial released on Tuesday. Novo Nordisk sells liraglutide as a diabetes and obesity drug under the brand names Victoza and Saxenda, respectively. Alzheimer's disease often causes the brain to shrink as the illness progresses because crucial nerve cells break down and stop working properly. By 2050, the number of Alzheimer's patients is projected to rise to almost 13 million in the U.S. The ongoing EVOKE is examining semaglutide, the active ingredient in Wegovy and Ozempic, in nearly 2,000 Alzheimer's patients.

Persons: George Frey, Eli Lilly, liraglutide, Brian B, Bettencourt, Heather Snyder, Leqembi, Snyder, Dr, Paul Edison, Edison, Bobby Pugh, Bessie Pugh, Karen Pulfer Focht Organizations: Novo Nordisk Pharmaceutical, Reuters, Novo Nordisk, Imperial College London, Alzheimer's Association International Conference, Toronto Star, Getty, Alzheimer's Association, U.S, CNBC, Alzheimer's, Novo Nordisk's, Ave Locations: Provo , Utah, Danish, Philadelphia, Biogen, Novo, Bartlett , Tennessee, U.S

☆ Ozempic predecessor suggests potential for GLP-1 drugs in Alzheimer’s in early trial
▼ + stars: | 2024-07-30 | by ( Meg Tirrell | ) edition.cnn.com time to read: +7 min

“This is the first study that actually looked at a relatively large number of patients for whether there is any neuroprotective effect in Alzheimer’s disease,” Edison said. The trial enrolled predominantly people with mild Alzheimer’s disease, measured by a test known as the Mini-Mental State Examination, a scale that goes up to 30. The GLP-1 drug class also includes Eli Lilly’s Mounjaro and Zepbound, which use the active ingredient tirzepatide, which mimics not just the hormone GLP-1 but another called GIP. But it hasn’t announced any trials of its GLP-1 drugs in Alzheimer’s. GLP-1 drugs can have side effects, though, primarily gastrointestinal problems like nausea and vomiting.

Persons: liraglutide, “, ”, Maria Carrillo, Carrillo, Paul Edison, ” Edison, Edison, Eli Lilly’s Mounjaro, Alzheimer’s Lilly, hasn’t, Lilly, Lars Fruergaard Jorgensen, there’s, Dr, Sanjay Gupta, semaglutide Organizations: CNN, Alzheimer’s Association International Conference, Alzheimer’s Association, Novo Nordisk, Imperial College London, ”, Nordisk, ” Novo Nordisk, CNN Health, University of Oxford, Alzheimer’s Society, Alzheimer’s Locations: United Kingdom, Philadelphia, Alzheimer’s, ” Novo, Danish

☆ Here are JPMorgan's top drug stock picks into earnings
▼ + stars: | 2024-07-29 | by ( Brian Evans | ) www.cnbc.com time to read: +3 min

JPMorgan is eyeing a few drug manufacturers ahead of their earnings reports as investors continue to sell out of major technology firms. This backdrop has analyst Chris Schott reviewing JPMorgan's top pharmaceutical and biotechnology stocks, which includes "stories that have clear upside potential to longer-term estimates" like Eli Lilly and Merck. Eli Lilly Pharmaceutical company Eli Lilly made the list. Schott said the firm is somewhat below consensus Wall Street estimates for Eli Lilly heading into second-quarter results on Aug. 8. LLY YTD mountain Eli Lilly stock.

Persons: Johnson, Merck —, Chris Schott, Eli Lilly, Merck, Schott, —, Regeneron Organizations: JPMorgan, Dow Jones, Johnson, Merck, US Major Pharma, Schott, FactSet, Pharmaceuticals Locations: Mounjaro, Novo

☆ Anxiety may increase risk of dementia, study finds
▼ + stars: | 2024-07-29 | by ( Kristen Rogers | ) edition.cnn.com time to read: +8 min

ingwervanille/Moment RF/Getty ImagesMore than 55 million people worldwide have dementia, a number expected to increase to 139 million by 2050. Previous studies exploring the relationship between anxiety and dementia have largely measured participants’ anxiety at one point in time, providing mixed conclusions — but how long someone’s anxiety lasts is an important aspect worth considering, the authors argued. Researchers measured participants’ anxiety at the first and second assessments. Someone’s anxiety was considered resolved if they had anxiety only at the time of the first wave. “This study agrees with earlier studies that therapy aimed at alleviating anxiety can help reduce risk for (Alzheimer’s disease).

Persons: ”, Kay Khaing, Glen R, Finney, ” Finney, wasn’t, “, Rudolph Tanzi, Dr, Joel Salinas, Isaac Health, Salinas wasn’t, Tanzi, Khaing, ” Khaing, ” Tanzi Organizations: CNN, American Geriatrics Society, Hunter New, Hunter New England Health, Getty, Australian Department of Health, American Academy of Neurology, McCance, Brain Health, Massachusetts General Hospital, NYU Langone Health, ”, National Alliance, Mental Locations: Hunter New England, Newcastle, Australia, Pennsylvania, Massachusetts, Boston, ” Salinas

☆ Investors are punishing stocks that miss earnings more than normal this season
▼ + stars: | 2024-07-29 | by ( Yun Li | ) www.cnbc.com time to read: +2 min

Companies with disappointing quarterly results are getting punished more than usual this earnings season. This phenomenon underscores the high expectations going into this season as well as a stock market that's viewed by many as overheated. Case in point, shares of Ford Motors plunged more than 18% on Thursday after the automaker came in short of earnings expectations due to warranty costs. "So far this earnings season, the results for many large bellwether companies have been better than the stock reactions," John Belton, portfolio manager at Gabelli Funds, said in an email. Investors will be closely watching this week's earnings slate , which includes Microsoft , Meta Platforms , Apple and Amazon .

Persons: FactSet, Peter Boockvar, Dexcom, John Belton Organizations: Bleakley Financial, CNBC, Ford Motors, JPMorgan Chase, Gabelli, Microsoft, Meta, Apple

☆ Popular weight-loss and diabetes medications show promise for curbing smoking, study suggests
▼ + stars: | 2024-07-29 | by ( Deidre Mcphillips | ) edition.cnn.com time to read: +4 min

But experts emphasize that much more research is needed before using the medications off-label for smoking cessation. In a study published Monday in the journal Annals of Internal Medicine, researchers tracked the medical records of more than 200,000 people who started medications to treat type 2 diabetes, including nearly 6,000 people using semaglutide medications such as Ozempic. Over the course of a year, people who started using semaglutide were significantly less likely to have medical encounters for tobacco use disorders, prescriptions for medications for smoking cessation or counseling for smoking cessation than those who started other diabetes medications such as insulin and metformin. “A signal like this one cannot be ignored, particularly because of how consequential it could be if, in fact, we can have now a new medication for treating smoking cessation,” she said. But fewer than 1 in 10 adult cigarette smokers succeed in quitting each year, according to the new study, and options for smoking cessation treatment haven’t changed much in decades.

Persons: Disha, ”, Nora Volkow, ” Volkow, Dr, Sanjay Gupta, Volkow Organizations: CNN, Internal Medicine, Endeavor Health, National Institute on Drug, Get CNN, CNN Health, US Centers for Disease Control, American Cancer Society Locations: Chicago, United States

☆ Swiss pharma giant Roche to accelerate Wegovy rival drugs after positive trial data
▼ + stars: | 2024-07-29 | by ( Karen Gilchrist | ) www.cnbc.com time to read: +2 min

Swiss pharmaceutical giant Roche said Monday it is accelerating the development of its Wegovy rival weight loss drugs following promising early stage trial data. However, in an FT interview published earlier Monday, CEO Thomas Schinecker indicated that the firm's first obesity drug could come to market "significantly faster than people are expecting," potentially by 2028. Both CT-388 and CT-996 were acquired as part of Roche's purchase of U.S. biotech company Carmot Therapeutics, which completed in January. The promising results could see Roche emerge as a potential rival to obesity drug pioneers Novo Nordisk and Eli Lilly. Schinecker told CNBC last week that he expects the company to eventually offer a suite of obesity medications.

Persons: Roche, Nordisk's Wegovy, Eli Lilly, Thomas Schinecker, Teresa Graham, Roche's, Schinecker Organizations: Nordisk's, CNBC, Roche Pharmaceuticals, Carmot Therapeutics, Novo Nordisk Locations: U.S

☆ Stocks making the biggest moves midday: Walt Disney, Dexcom, McDonald's, On Semiconductor and more
▼ + stars: | 2024-07-29 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +2 min

Revvity — The life sciences company advanced 6% after posting a second-quarter earnings beat. Revvity's adjusted earnings of $1.22 per share topped the FactSet estimate of $1.12 per share. The new Marvel movie topped $200 million at the domestic box office, a record opening weekend for an R-rated film. Second-quarter adjusted earnings per share came in at 96 cents, versus the expected consensus estimate of 92 cents, per FactSet. The stock plunged more than 40% in the previous session after Dexcom reported disappointing second-quarter results and offered weak guidance.

Persons: Tesla, Morgan Stanley, Adam Jonas, Walt Disney, Dexcom, — CNBC's Sean Conlon, Michelle Fox, Alex Harring, Jesse Pound, Samantha Subin Organizations: Management, Guggenheim, Ford, Deutsche Bank, Walt Disney —, Marvel, Semiconductor —, Revenue, Dexcom, Health Canada

☆ These drugmakers are catching up to Eli Lilly and Novo Nordisk in weight loss treatments
▼ + stars: | 2024-07-28 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +6 min

With billions at stake, that's pretty much been a guarantee facing the current market leaders, Eli Lilly and Novo Nordisk , from the start. Their updates are likely to be joined by others in the coming months even as today's incumbents develop their own next-generation weight loss treatments. Other analysts have also grown more optimistic about the future of weight loss treatments. Orforglipron, a once-a-day oral GLP-1 drug that Lilly is working on, had shown a 3% weight loss at 4 weeks. The company is also exploring whether the weight loss treatment could be given only once a month.

Persons: Eli Lilly, drugmakers Roche, Lilly, Denmark's, Trung Huynh, Huynh, Rajesh Kumar, Kumar, Novo, Roche, Roche ADRs, Justin Zelin, Zelin, Viking's, HSBC's Kumar, Novo aren't, —, Nick Wells Organizations: Novo Nordisk, Viking Therapeutics, UBS, HSBC Global Research, Carmot Therapeutics, Food and Drug Administration, Viking, European Association for, Diabetes, Pfizer, Amgen, Therapeutics Locations: Swiss, Novo, San Antonio, Spain

☆ Alzheimer’s blood test catches 90% of early dementia cases, study finds
▼ + stars: | 2024-07-28 | by ( Sandee Lamotte | ) edition.cnn.com time to read: +10 min

CNN —A combined blood test for cognitive decline has a 90% accuracy rate in determining whether memory loss is due to Alzheimer’s disease, a new study found. “The p-tau217 blood test is turning out to be the most specific for Alzheimer’s and the one with the most validity. “These are absolutely transformational times.”How does a p-tau217 blood test work? The results of the blood tests were then measured against patient diagnoses provided by Swedish primary care doctors and specialists. “There’s no one more bullish on these tests than I am, but Alzheimer’s blood tests aren’t fully definitive yet,” he said.

Persons: CNN —, Sebastian Palmqvist, ” Palmqvist, ”, Maria Carrillo, Carrillo, “ You’re, that’s, ” Carrillo, “, ” Tau tangles, Richard Isaacson, Oskar Hansson, ” Hansson, Hansson, Isaacson, ” Isaacson Organizations: CNN, Lund University, “, Alzheimer’s Association, International Conference Locations: Sweden, Alzheimer’s, Florida, United States, Philadelphia

☆ An ugly earnings report from a competitor is good news for Abbott Labs
▼ + stars: | 2024-07-26 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +3 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. In the wreckage of Dexcom 's second-quarter earnings report, there's good news for Club holding Abbott Laboratories . As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, Stocks, Stanley Black, Decker, Abbott, Dexcom, salesforce, Jim Cramer's, ABT, DOV, Jim Organizations: CNBC, Dow Jones, Nasdaq, Federal, U.S, Club, Abbott Laboratories, Dover, Mizuho Securities Locations: Dover

☆ Beyond Novo and Eli Lilly: Watch these biotech and weight loss drug names, fund manager says
▼ + stars: | 2024-07-26 | by ( Weizhen Tan | ) www.cnbc.com time to read: +3 min

Weight loss drugs have drawn investor interest and shaken up other sectors in the past year or so. Novo Nordisk and Eli Lilly were two early winners of this trend, as their drugs dominate the weight loss drug market. Yuri Khodjamirian, fund manager at Tema ETFs, said both companies are a "very powerful duopoly." They're a lot more risky than the bigger ones who already have drugs on the market," Khodjamirian said. Tema ETFs offers actively managed exchange-traded funds, with a focus on health care and life sciences.

Persons: Eli Lilly, Yuri Khodjamirian, Goldman Sachs, Khodjamirian, Roche Organizations: Novo Nordisk, Tema, CNBC, Zealand Pharma, Viking Therapeutics, Tema Oncology, Mental Health Locations: Tema

☆ Dexcom shares plunge more than 40%, head for worst day on record
▼ + stars: | 2024-07-26 | by ( Ashley Capoot | In | ) www.cnbc.com time to read: +4 min

Dexcom shares sank more than 40% on Friday and headed for their worst day ever after the diabetes management company reported disappointing revenue for the second quarter and offered weak guidance. The stock fell $45.38 to $62.47 as of early afternoon, wiping out about $18 billion in market cap. Prior to Friday, the biggest drop came in September 2017, when the shares plunged 33% in a day. Dexcom held its stock market debut in 2005. With Friday's selloff, Dexcom shares are down almost 50% for the year, while the S&P 500 is up 15%.

Persons: Dexcom, Kevin Sayer, we've, Sayer, JPMorgan's Robbie Marcus, Marcus, Jereme Sylvain, Sylvain, William Blair, Leerink, Stelo, Friday's Organizations: JPMorgan, U.S . Food, Drug Administration

☆ Should I use a smartwatch to track my health data? A doctor explains
▼ + stars: | 2024-07-26 | by ( Katia Hetter | ) edition.cnn.com time to read: +9 min

To sort out my smartwatch health and fitness questions, I spoke with CNN wellness expert Dr. Leana Wen. A smartwatch with a heart rate monitor can help athletes track their heart rates to keep them in a certain range. Wen: What a lot of active people do is to track heart rate during exercise to keep the heart rate in a certain range. This is where the heart rate is under 70% to 75% of your maximal heart rate. Many smartwatches track sleep and can tell you how long you’ve slept and how much time you spent in each sleep stage.

Persons: CNN —, Leana Wen, Wen, I’ve, aren’t, it’s Organizations: CNN, Intelligence, George Washington University, Bluetooth, Apple Watch, Samsung Galaxy, US Food and Drug Administration, FDA Locations: what’s

☆ Viking Therapeutics stock jumps 30% after drugmaker moves weight loss injection to late-stage trial
▼ + stars: | 2024-07-25 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Shares of Viking Therapeutics jumped more than 30% on Thursday after the biotech company a day earlier announced plans to advance its experimental weight loss injection into a late-stage trial earlier than expected. Viking is one of several small and large drugmakers hoping to compete in the space against Novo Nordisk and Eli Lilly , whose weight loss and diabetes GLP-1s have skyrocketed in demand over the last two years. During the call, Lian added that Viking expects to test VK2735 as a monthly injection in a future study. Viking Therapeutics' drug promotes weight loss by targeting a GLP-1 and another hormone called GIP. That pill caused 3.3% weight loss when compared to a placebo in an early-stage trial.

Persons: Eli Lilly, Viking, Brian Lian, Lian, Justin Zelin, Zelin, Eli Lilly's Zepbound Organizations: Viking Therapeutics, San, Novo Nordisk, Food and Drug Administration, FDA, Novo Nordisk's Wegovy Locations: San Diego

Search resuls for: "Diabetes"

25 mentions found